Gencor has received approval from Health Canada for four health claims on its standardized fenugreek extract, Libifem. These health claims are based on scientific and clinical data supporting each benefit. Products in Canada can now claim the following: 
 

• Helps to increase women’s sexual desire
• Helps support women’s healthy sex drive and libido
• Helps promote women’s sexual arousal
• May help reduce menopausal symptoms such as hot flashes and night sweats

 
“Receiving all four health claims further validates our research on Libifem and its ability to help reduce menopausal symptoms and promote healthy sexual activity,” said Chase Shryoc, Gencor’s VP of sales and business development. “Libifem is proving to be a well-rounded ingredient for women. We are currently conducting clinical trials to see its potential benefits for women in sports nutrition applications.”
 
Libifem has numerous clinical trials backing its efficacy and continues to be a top-selling ingredient for Gencor. Libifem has obtained GRAS status and is a standardized extract of fenugreek that contains Furostanol and Steroidal Saponins. It is a patented, single herb extract that can easily be incorporated into a variety of applications, including powders, tablets, soft gels, and capsules. Libifem is part of Gencor’s portfolio of healthy ingredients for women, each of which are backed by scientific studies and based on the various stages of a woman’s life.